Home › Funds › Cormorant Asset Management, LP › RAPP
Cormorant Asset Management, LP position in RAPP
RAPPORT THERAPEUTICS INC · Health Care
Cormorant Asset Management, LP reported holding 2,657,521 shares of RAPP (RAPPORT THERAPEUTICS INC) in its Q2 2026 13F filing — a position valued at US$110.7M, representing 5.67% of its reported portfolio and ranking #4 among its reported holdings. Cormorant Asset Management, LP has disclosed RAPP holdings in 9 of the last 9 reported quarters, going back to Q2 2024.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Cormorant Asset Management, LP's RAPP position evolved
Cormorant Asset Management, LP first disclosed a stake in RAPP in Q2 2024 at 2,940,283 shares (US$68.4M). The position peaked in Q2 2026 at 2,657,521 shares, worth US$110.7M. Across 9 filings, Cormorant Asset Management, LP increased the stake 1 time(s), trimmed it 3 time(s) and left it unchanged 4 time(s). The most recent filing (Q2 2026) shows 2,657,521 shares valued at US$110.7M — a reduction of -300,000 shares quarter over quarter..
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q2 2024 | 2.94M | $68.39M | New |
| Q3 2024 | 2.94M | $60.23M | Hold |
| Q4 2024 | 2.94M | $52.17M | Hold |
| Q1 2025 | 2.94M | $29.50M | Hold |
| Q2 2025 | 2.94M | $33.44M | Hold |
| Q3 2025 | 3.19M | $94.82M | Add |
| Q4 2025 | 3.03M | $91.85M | Reduce |
| Q1 2026 | 2.96M | $92.54M | Reduce |
| Q2 2026 | 2.66M | $110.74M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About RAPP and 13F data
RAPP (RAPPORT THERAPEUTICS INC) is a Health Care company. 66 other funds we track also report a position in RAPP — the largest reported positions include TRV GP V, LLC (US$261.7M), ARCH Venture Management, LLC (US$155.4M), Sofinnova Investments, Inc. (US$79.4M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding RAPP
- TRV GP V, LLC 6.28M sh · $261.71M · Q2 2026
- ARCH Venture Management, LLC 3.73M sh · $155.38M · Q2 2026
- Sofinnova Investments, Inc. 1.90M sh · $79.36M · Q2 2026
- JOHNSON & JOHNSON 1.78M sh · $74.36M · Q2 2026
- BAKER BROS. ADVISORS LP 1.55M sh · $64.47M · Q2 2026
- TRV GP VI, LLC 969.22K sh · $40.39M · Q2 2026
- PERCEPTIVE ADVISORS LLC 773.34K sh · $32.23M · Q2 2026
- Vestal Point Capital, LP 730.00K sh · $30.42M · Q2 2026
- Siren, L.L.C. 641.47K sh · $26.73M · Q2 2026
- Sio Capital Management, LLC 307.66K sh · $12.82M · Q2 2026
- Burkehill Global Management, LP 250.00K sh · $10.42M · Q2 2026
- Artia Global Partners LP 138.51K sh · $5.77M · Q2 2026
More on Cormorant Asset Management, LP
FAQ
How long has Cormorant Asset Management, LP held RAPP?
Cormorant Asset Management, LP has disclosed RAPP holdings in 9 of the last 9 reported quarters, going back to Q2 2024.
What is Cormorant Asset Management, LP's current position in RAPP?
As of Q2 2026, Cormorant Asset Management, LP holds 2.66M shares of RAPP (RAPPORT THERAPEUTICS INC), valued at $110.74M, representing 5.67% of its reported portfolio and ranking #4.
Has Cormorant Asset Management, LP been buying or selling RAPP?
In the latest 13F filing (Q2 2026), Cormorant Asset Management, LP reduced its position in RAPP. The position peaked in Q2 2026 at 2.66M shares.
Which other funds hold RAPP?
Other major institutional holders of RAPP include TRV GP V, LLC, ARCH Venture Management, LLC, Sofinnova Investments, Inc., among 66 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.